A fully magnetically levitated circulatory pump for advanced heart failure

Mandeep R. Mehra, Yoshifumi Naka, Nir Uriel, Daniel J. Goldstein, Joseph C. Cleveland, Paolo C. Colombo, Mary N. Walsh, Carmelo A. Milano, Chetan B. Patel, Ulrich P. Jorde, Francis D. Pagani, Keith D. Aaronson, David A. Dean, Kelly McCants, Akinobu Itoh, Gregory A. Ewald, Douglas Horstmanshof, James W. Long, Christopher Salerno

Research output: Contribution to journalArticle

363 Scopus citations

Abstract

BACKGROUND Continuous-flow left ventricular assist systems increase the rate of survival among patients with advanced heart failure but are associated with the development of pump thrombosis. We investigated the effects of a new magnetically levitated centrifugal continuous-flow pump that was engineered to avert thrombosis. METHODS We randomly assigned patients with advanced heart failure to receive either the new centrifugal continuous-flow pump or a commercially available axial continuous-flow pump. Patients could be enrolled irrespective of the intended goal of pump support (bridge to transplantation or destination therapy). The primary end point was a composite of survival free of disabling stroke (with disabling stroke indicated by a modified Rankin score >3; scores range from 0 to 6, with higher scores indicating more severe disability) or survival free of reoperation to replace or remove the device at 6 months after implantation. The trial was powered for noninferiority testing of the primary end point (noninferiority margin, -10 percentage points). RESULTS Of 294 patients, 152 were assigned to the centrifugal-flow pump group and 142 to the axial-flow pump group. In the intention-To-Treat population, the primary end point occurred in 131 patients (86.2%) in the centrifugal-flow pump group and in 109 (76.8%) in the axial-flow pump group (absolute difference, 9.4 percentage points; 95% lower confidence boundary, -2.1 [P<0.001 for noninferiority]; hazard ratio, 0.55; 95% confidence interval [CI], 0.32 to 0.95 [two-Tailed P = 0.04 for superiority]). There were no significant between-group differences in the rates of death or disabling stroke, but reoperation for pump malfunction was less frequent in the centrifugal- flow pump group than in the axial-flow pump group (1 [0.7%] vs. 11 [7.7%]; hazard ratio, 0.08; 95% CI, 0.01 to 0.60; P = 0.002). Suspected or confirmed pump thrombosis occurred in no patients in the centrifugal-flow pump group and in 14 patients (10.1%) in the axial-flow pump group. CONCLUSIONS Among patients with advanced heart failure, implantation of a fully magnetically levitated centrifugal-flow pump was associated with better outcomes at 6 months than was implantation of an axial-flow pump, primarily because of the lower rate of reoperation for pump malfunction.

Original languageEnglish (US)
Pages (from-to)440-450
Number of pages11
JournalNew England Journal of Medicine
Volume376
Issue number5
DOIs
StatePublished - Feb 2 2017

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A fully magnetically levitated circulatory pump for advanced heart failure'. Together they form a unique fingerprint.

  • Cite this

    Mehra, M. R., Naka, Y., Uriel, N., Goldstein, D. J., Cleveland, J. C., Colombo, P. C., Walsh, M. N., Milano, C. A., Patel, C. B., Jorde, U. P., Pagani, F. D., Aaronson, K. D., Dean, D. A., McCants, K., Itoh, A., Ewald, G. A., Horstmanshof, D., Long, J. W., & Salerno, C. (2017). A fully magnetically levitated circulatory pump for advanced heart failure. New England Journal of Medicine, 376(5), 440-450. https://doi.org/10.1056/NEJMoa1610426